We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

168 hedge funds and large institutions have $987M invested in Karyopharm Therapeutics in 2020 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 61 increasing their positions, 44 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 21

40% more call options, than puts

Call options by funds: $11.2M | Put options by funds: $7.99M

39% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 44

7% more funds holding

Funds holding: 157 → 168 (+11)

4% more capital invested

Capital invested by funds: $949M → $987M (+$38.7M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.13% less ownership

Funds ownership: 5.91% → 5.78% (-0.13%)

Holders
168
Holders Change
+11
Holders Change %
+7.01%
% of All Funds
2.97%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
32
Increased
61
Reduced
44
Closed
21
Calls
$11.2M
Puts
$7.99M
Net Calls
+$3.23M
Net Calls Change
+$273K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$36M
2
LCM
Laurion Capital Management
New York
+$12.8M
3
CWG
C WorldWide Group
Denmark
+$9.27M
4
State Street
State Street
Massachusetts
+$8.51M
5
Alkeon Capital Management
Alkeon Capital Management
New York
+$7.75M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$87.6M
2
Two Sigma Investments
Two Sigma Investments
New York
-$19.3M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$15.5M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$11.6M
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$10.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Tudor Investment Corp
176
Tudor Investment Corp
Connecticut
– -$473K -2,161 Closed
TC
177
TwinBeech Capital
New York
– -$425K -1,942 Closed
QI
178
QS Investors
New York
– -$422K -1,927 Closed
SFI
179
Susquehanna Fundamental Investments
Pennsylvania
– -$371K -1,694 Closed
ECM
180
ExodusPoint Capital Management
New York
– -$331K -1,513 Closed
Axa
181
Axa
France
– -$321K -1,467 Closed
EWM
182
Edge Wealth Management
New York
– -$130K -593 Closed
GT
183
Glenmede Trust
Pennsylvania
– -$42K -193 Closed
QT
184
Quantbot Technologies
New York
– -$29K -136 Closed
PHK
185
Point72 Hong Kong
Hong Kong
– -$20K -92 Closed
CHAM
186
Clear Harbor Asset Management
Connecticut
– -$14.6K -67 Closed
Northwestern Mutual Wealth Management
187
Northwestern Mutual Wealth Management
Wisconsin
– -$14K -65 Closed
CCM
188
Chiron Capital Management
Florida
– -$12K -53 Closed
PFWA
189
Paces Ferry Wealth Advisors
Georgia
– -$1K -3 Closed
4 5 6 7
8

KPTI Hedge Fund Activity: Q4 2020 in Review

168 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2020, worth a combined $987M — up 4.1% from $949M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new KPTI positions and 21 closed out — a net gain of 11 holders — while 61 added to existing stakes and 44 trimmed.

The largest buyer was Millennium Management, adding an estimated $36M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $87.6M sold.

  • 168 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2020, up from 157 in Q3 2020.
  • Funds reported $987M of Karyopharm Therapeutics stock for Q4 2020, up 4.1% quarter-over-quarter.
  • 32 funds opened new Karyopharm Therapeutics positions in Q4 2020 and 21 closed out, a net change of +11 holders.
  • The largest Karyopharm Therapeutics buyer in Q4 2020 was Millennium Management, an estimated $36M added.
  • The largest Karyopharm Therapeutics seller in Q4 2020 was Avoro Capital Advisors, an estimated $87.6M sold.

Based on aggregated 13F filings for Q4 2020.